Core Insights - HCA Healthcare reported a revenue increase of 6.7% year-over-year for Q4 2025, with net income rising nearly 31% and adjusted EBITDA increasing about 11% compared to the prior year [1][5][7] Financial Performance - The company achieved its 19th consecutive quarter of volume growth, with a record of approximately 47 million patient encounters in 2025 [2][5] - Full-year 2025 results showed a consolidated adjusted EBITDA growth of 12.1% and a 90-basis-point improvement in adjusted EBITDA margin [7] - For Q4 2025, same-facility net revenue per equivalent admission increased by 2.9% year-over-year, with equivalent admissions growth of 2.4% [5][7] Capital Allocation and Investments - HCA Healthcare deployed significant capital in 2025, with capital expenditures of $4.9 billion and share repurchases totaling $10 billion [4][12] - The company announced a new $10 billion share repurchase program and increased its quarterly dividend to $0.78 per share from $0.72 [16] 2026 Outlook - For 2026, HCA Healthcare guided revenue between $76.5 billion and $80 billion, with adjusted EBITDA projected at $15.55 billion to $16.45 billion [3][9] - The guidance includes anticipated headwinds from health insurance exchange reforms and supplemental payment program changes, with an expected EBITDA impact of $600 million to $900 million [3][13] Operational Strategies - Management emphasized disciplined capital allocation and improvements in capacity management and quality outcomes as key drivers of performance [2][3] - The company is focusing on resiliency initiatives to offset expected declines in health insurance exchange volumes, with a projected 15% to 20% decline in 2026 [11][12][15] Outpatient Services - HCA Healthcare continues to invest heavily in outpatient facilities, adding approximately 100 outpatient business units in 2025 [20] - Outpatient revenue growth outpaced inpatient growth, although same-facility outpatient surgery cases saw a slight decline [19][20]

Financial Data and Key Metrics Changes - Revenue increased by 6.7% compared to the prior year quarter, with net income attributable to HCA Healthcare rising almost 31% [4][11] - Diluted earnings per share as adjusted increased by 29%, and adjusted EBITDA grew around 11% versus the prior year period [4][11] - For the full year 2025, consolidated adjusted EBITDA increased by 12.1% over the prior year, with a 90 basis point improvement in adjusted EBITDA margins [11] Business Line Data and Key Metrics Changes - Same-facility admissions increased by 2.4%, and equivalent admissions increased by 2.5%, aligning with expectations of 2%-3% growth [9] - Inpatient surgeries were flat, while outpatient surgical volume decreased slightly [9] - ER visits increased by 50 basis points, with overall respiratory volumes having no material impact on year-over-year volume [9] Market Data and Key Metrics Changes - Same facility total commercial equivalent admissions increased by 1.1% over the prior year, with Medicare increasing by 3.5% and Medicaid by 2.2% [9][10] - Same-facility net revenue per equivalent admission increased by 2.9% versus the prior year quarter [10] Company Strategy and Development Direction - The company is focused on network expansion, workforce development, and clinical capabilities, which have contributed to positive outcomes across the HCA Healthcare system [5][6] - The Resiliency Program was strengthened in organizational capabilities, competitive positioning, and financial management, aiming to navigate policy dynamics effectively [6] - The company plans to invest significantly in technology and digital innovation strategies to deliver long-term value [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the core business, forecasting volumes in a long-term growth range of 2%-3% [6] - The company anticipates adverse impacts on adjusted EBITDA between $600 million and $900 million related to health insurance exchanges due to administrative reforms and the expiration of enhanced premium tax credits [14] - Management remains optimistic about operational performance and believes the company is well-positioned for continued progress in 2026 [16] Other Important Information - Capital expenditures totaled $1.5 billion in the quarter and $4.9 billion for the year, with a new $10 billion share repurchase program authorized by the board [11][15] - The quarterly dividend was increased from $0.72 to $0.78 per share [15] Q&A Session Summary Question: Can you talk about the expense items and margin improvement opportunities for 2026? - Management indicated expectations for stable margins in 2026, with continued physician cost pressures anticipated [19][20] Question: Can you provide more detail on the resiliency programs and their impact? - The resiliency program focuses on revenue integrity, cost efficiencies, and capacity management, with a target of $400 million in incremental cost savings for 2026 [24][25] Question: What is the expected impact of the health insurance exchange headwinds on volume? - Management anticipates a 15%-20% decline in HIX volumes for 2026, with a significant portion migrating to uninsured status, leading to a decline in utilization [26][66] Question: Can you elaborate on the pause of Texas Medicaid supplemental payments? - The Texas Medicaid program is under review, and its potential reinstatement could impact the overall guidance for 2026 [96] Question: What are the expectations for growth in specialties and procedures in 2026? - Management noted reasonable demand for cardiac services and emphasized investments in emergency room services and outpatient facilities [88][89]

Financial Data and Key Metrics Changes - The company reported a 42% growth in diluted earnings per share as adjusted compared to the previous year [4] - Revenue increased by 9.6%, driven by broad-based volume growth, improved payer mix, and additional revenue from Medicaid supplemental programs [4][5] - Adjusted EBITDA margin improved due to strong performance in labor and supplies management [13] Business Line Data and Key Metrics Changes - Same facility equivalent admissions increased by 2.4% year-over-year [10] - Inpatient surgical volume grew by 1.4% and outpatient surgical volume by 1.1% [10] - Same facility total commercial equivalent admissions rose by 3.7%, with exchanges growing by 8% and commercial (excluding exchanges) by 2.4% [11] Market Data and Key Metrics Changes - Commercial and Medicare ER visits combined increased by 4.1% year-over-year, while Medicaid and self-pay ER visits declined [10] - The company experienced a slow start to the respiratory season, impacting admissions and ER visits growth rates by an estimated 50 and 70 basis points, respectively [10] Company Strategy and Development Direction - The company is focused on enhancing capacity, improving service offerings, and gaining efficiency through investments in advanced digital tools and training [5][8] - The management team has been restructured to strengthen enterprise capabilities and improve operational execution [8] - The company is advocating for the extension of enhanced premium tax credits for health insurance coverage [6] Management's Comments on Operating Environment and Future Outlook - Management expects solid demand for healthcare services to continue, with volumes projected to grow within a long-term range of 2% to 3% [7] - Operating costs are anticipated to remain stable, with some pressures in certain areas, but the resiliency plan is expected to provide relief [7] - The company is well-positioned to sustain high levels of performance in the coming years [8] Other Important Information - Cash flow from operations was $4.4 billion, with $1.3 billion in capital expenditures and $2.5 billion in share repurchases [15] - The company updated its full-year guidance, expecting revenues between $75 billion and $76.5 billion and adjusted EBITDA between $15.25 billion and $15.65 billion [16] Q&A Session Summary Question: Can you remind us what states are still pending for grandfather programs? - Management mentioned Florida, Georgia, and Virginia as states with pending applications, but they do not expect approvals during the shutdown [22] Question: Are you seeing early scheduling for surgeries due to potential coverage loss? - Management indicated that it is too early to size the potential impact of enrollment changes, but they are prepared to assist patients with coverage navigation [30] Question: Can you provide insight into the guidance range for the fourth quarter? - Management expects a solid growth rate in the high single digits for the fourth quarter, considering hurricane impacts and supplemental payment declines [36] Question: How much of the supplemental payments were recognized in the third quarter? - Tennessee was the largest driver of net benefit in the third quarter, with Texas and Kansas also contributing to the supplemental payments [39][40] Question: What is the outlook for professional fees and their impact on EBITDA? - Professional fees increased by 11% year-over-year, primarily related to anesthesia and radiology [91]